CEO Today United Kingdom Awards

www.ceotodaymagazine.com 94 CEO Today United Kingdom Awards 2018 PHARMACEUTICALS SIGGI OLAFSSON CEO of HIKMA PHARMACEUTICALS PLC FIRM PROFILE Our vision Our vision is of a healthier world that enriches all of our communities. Throughout our last 40 years, we’ve been guided by the simple belief that when world-class medicine is put within people’s reach, it has the ability to transform their lives and their communities. Today at Hikma we now have the reach, insight and expertise to transform so many more people’s lives. And in a fast-changing world, our commitment to our vision is as important as ever – not only for Hikma, but also for the millions of people we serve around the world. Our values Our four values are the collectively held principles of our people that shape the way we think, work and behave: • Integrity: Acting with honesty and honour without compromising the truth. • Excellence: Holding people accountable to the highest standards of performance. • Respect: Showing consideration for one another, recognising each other’s differences, needs and expectations. • Transparency: Embodying openness, communication and accountability. Operating clearly and openly, making it easy for others to observe performance. ABOUT SIGGI OLAFSSON Siggi has significant international experience in the pharmaceutical industry. From 2012 to 2014, he was President of Actavis, which was then acquired by Teva Pharmaceuticals where he was appointed President and Chief Executive Officer of the Global Generic Medicines Group until 2017. Prior to this, he was Executive Vice President, Global Generics, at Actavis plc (Watson) from 2010 to 2012; and CEO of the Actavis Group from 2008 to 2010. From 2003 to 2008, he held positions of increasing responsibility within the Actavis Group, including Deputy CEO, Vice President of Corporate Development and CEO of Actavis Inc. U.S. From 1998 to 2003, he held positions of increasing responsibility with Pfizer’s Global R&D organization in the U.K. and U.S. From 1994 to 1998, he served as Head of Drug Development for Omega Farma in Iceland. He currently serves as a member of the board of directors for Elucida Oncology and Pfenex. M.S. in pharmacy (Cand Pharm) from the University of Iceland, Reykjavik. Other Appointments: Siggi is an independent director of Pfenex Inc., a biologics company listed on the New York Stock Exchange and a director at Elucida Oncology Inc. and an executive trustee of the American-Scandinavian Foundation.